Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
View Patent ↗The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
1. A method of monitoring cardiorenal syndrome a patient, comprising:
(a) performing an assay method that detects NGAL on a body fluid sample obtained from said patient, thereby providing an NGAL assay result;
(b) performing an assay method that detects one or more of BNP, NT-proBNP and proBNP on the same or a different body fluid sample obtained from said patient, thereby providing a natriuretic peptide assay result; and
(c) relating the NGAL assay result and the natriuretic peptide assay result to the patient's cardiorenal syndrome status by
(i) comparing said NGAL assay result to a baseline NGAL result, and assigning a worsening cardiorenal syndrome status to said patient when said NGAL assay result is greater than said baseline NGAL result, relative to a status assigned when said NGAL assay result is less than said baseline NGAL result, or by assigning an improving cardiorenal syndrome status to said patient when said NGAL assay result is less than said baseline NGAL result, relative to a status assigned when said NGAL assay result is greater than said baseline NGAL result, and
(ii) comparing said natriuretic peptide assay result to a baseline natriuretic peptide result, and assigning a worsening cardiorenal syndrome status to said patient when said natriuretic peptide assay result is greater than said baseline natriuretic peptide result, relative to a status assigned when said natriuretic peptide assay result is less than said baseline natriuretic peptide result, or by assigning an improving cardiorenal syndrome status to said patient when said natriuretic peptide assay result is less than said baseline natriuretic peptide result, relative to a status assigned when said natriuretic peptide assay result is greater than said baseline natriuretic peptide result.
2. A method according to claim 1 , wherein said baseline NGAL result is determined by performing an assay method that detects NGAL on a body fluid sample obtained from said patient at a time earlier than the time at which the body fluid sample used to provide said NGAL assay result was obtained.
3. A method according to claim 1 , wherein said baseline natriuretic peptide result is determined by performing an assay method that detects one or more of BNP, NT-proBNP and proBNP on a body fluid sample obtained from said patient at a time earlier than the time at which the body fluid sample used to provide said natriuretic peptide assay result was obtained.
4. A method according to claim 1 , wherein said baseline NGAL result is determined from a population of subjects suffering from cardiorenal syndrome, and said baseline NGAL result is selected to separate said population into a first subpopulation having a worsening cardiorenal syndrome status relative to a second subpopulation.
5. A method according to claim 1 , wherein said baseline natriuretic peptide result is determined from a population of subjects suffering from cardiorenal syndrome, and said baseline natriuretic peptide result is selected to separate said population into a first subpopulation having an worsening cardiorenal syndrome relative to a second subpopulation.
6. A method according to claim 4 , wherein said baseline NGAL result separates said first subpopulation from said second subpopulation with an odds ratio of at least 2 or more or 0.5 or less.
7. A method according to claim 4 , wherein said baseline NGAL result separates said first subpopulation from said second subpopulation with an odds ratio of at least 3 or more or 0.33 or less.
8. A method according to claim 5 , wherein said baseline natriuretic peptide result separates said first subpopulation from said second subpopulation with an odds ratio of at least 2 or more or 0.5 or less.
9. A method according to claim 5 , wherein said baseline natriuretic peptide result separates said first subpopulation from said second subpopulation with an odds ratio of at least 3 or more or 0.33 or less.
10. A method according to claim 1 , wherein the assay method that detects NGAL comprises performing an immunoassay that detects NGAL, and the assay method that detects one or more of BNP, NT-proBNP and proBNP comprises performing an immunoassay that detects one or more of BNP, NT-proBNP and proBNP.
11. A method according to claim 1 , wherein the body fluid sample is selected from the group consisting of urine, blood, serum, and plasma.